GLP-1 Drugs Reduce Rheumatoid Arthritis Symptoms
MedPage Today
Recent News
Patients with rheumatoid arthritis (RA) who used GLP-1 receptor agonists had less disease activity and improved cardiovascular biomarkers, a small retrospective study indicated.Read Article
What you need to know about scleroderma-related lung fibrosis
What do you need to know about scleroderma-related lung fibrosis as a practicing rheumatologist? Here are takeaways from these guidelines and my practice.
Read Article
ILD and Mortality in Systemic Autoimmune Rheumatic Diseases
Dr. Bryant England, Lincoln, NE, discusses interstitial lung disease and mortality in systemic autoimmune rheumatic diseases (SARDs), as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month https://t.co/wtg9Te6oth
Dr. John Cush @RheumNow ( View Tweet)
Equal Safety of JAK Inhibitors and TNF Inhibitors
JAMA has published a systematic review and meta-analysis of head-to-head studies showing there was no meaningful difference in safety events observed when taking either JAK inhibitor (JAKi) vs TNF antagonist (TNFi) therapies for https://t.co/HI1KBKZiXR
Dr. John Cush @RheumNow ( View Tweet)
SARD-ILD and serious infection risk: The elephant in the room
Interstitial lung disease (ILD) remains one of the largest unmet clinical needs across many systemic autoimmune rheumatic diseases (SARD). ILD is highly prevalent across systemic sclerosis, mixed connective tissue https://t.co/oxIteGfUTd
Dr. John Cush @RheumNow ( View Tweet)
QD Clinic: Application of the ACR CHEST Guidelines to Two Cases
Dr. Sindhu Johnson, Toronto, discusses two cases that where the application of the ACR CHEST guidelines for the screening, monitoring and treatment of SSc-ILD and Rapidly Progressive ILD are applied, as part of https://t.co/ntW2WIvJ8c
Dr. John Cush @RheumNow ( View Tweet)
CDC 2025–26 Updates to Influenza Vaccination.
- Most are trivalent inactivated (IIV3s) or vaccines (RIV3), few live virus(LAIV3)
- FDA approved FluMist (LAIV3) for self-administration (ages 2-49)
- If <18yrs, Flu vax should thimerosal free
2023/24 Flu vax prevented 7900 deaths, https://t.co/hjLBGKWNDr
Dr. John Cush @RheumNow ( View Tweet)
Patient Resource: The Hidden Connection - ILD and Rheumatic Disease
Dr. Iazsmin Bauer Ventura, Chicago, talks about ILD as a window to systemic disease as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025. https://t.co/8rJm4O3hHU
Dr. John Cush @RheumNow ( View Tweet)
RA-associated interstitial lung disease or bronchiectasis is assoc w/ increased risk of total and cause-specific mortality. retrospective cohort study using the Mass General Brigham Biobank 221 RA-LD cases (151 RA-ILD, 70 RA-BR). RA-LD higher mortality (34 vs 13/1000PY; HR
Dr. John Cush @RheumNow ( View Tweet)
When Myositis Hits the Lungs: What Every Rheumatologist Should Know About ILD
When idiopathic inflammatory myopathies (IIM) affect the lungs, the consequences can be serious. Interstitial lung disease (ILD) is not only common in IIM, but also one of the leading causes of death, https://t.co/qRoTr3r84x
Dr. John Cush @RheumNow ( View Tweet)
GLP-1 drugs cost-effective for knee osteoarthritis and obesity
EurekAlert!
A new study led by investigators at Mass General Brigham finds that adding novel weight loss GLP-1 drugs semaglutide and tirzepatide to usual care represents a cost-effective treatment strategy for people with knee osteoarthritis and obesity, with tirzepatide providing greater health benefits at lower cost compared to semaglutide.
Read Article
SARD-ILD: Significant diagnostic and treatment delays
Should we be screening all our patients with systemic autoimmune rheumatic disease (SARD) for interstitial lung disease? I have been asking myself that question after the recent publication of American Thoracic Society Interstitial Lung Disease screening guidelines. The ATS guidelines, which were published in May, recommend universal CT chest screening for all asymptomatic patients with RA, systemic sclerosis, idiopathic inflammatory
Read Article
STOP-RA: Hydroxychloroquine Fails in ACPA+ Arthralgia
Deane et al has published the results of the STOP-RA trial, demonstrating that 12 months of hydroxychloroquine (HCQ) did not prevent the development of clinical RA at 36 months.
https://t.co/HLLhwgcVrS https://t.co/MKpeXhVdoe
Links:
Dr. John Cush @RheumNow ( View Tweet)
Retrospective study of 201 IPAF (Interstitial pneumonia w/ autoimmune feat.) pts w/ F/U 5.6 yrs. ANA+ 80%, RF+ 25%, CCP+ 14%, 88% Rx w/ IS or antifibrotics. 24% died, 7.5% transplant. Comorbidies were common; mean CCI 3.2; IPAF mortality worsened by
Dr. John Cush @RheumNow ( View Tweet)
Commercial claims analysis of 8855 adults w/ axSpA and/or PsA, 1771 who had joint replacements. JAK inhibitor use did not significantly reduce joint replacement (OR 0.67; 0.41–1.08), BUT TNFi, Non-TNFi biologics & DMARD users had signif fewer surgeries (OR ~0.65) vs NSAID users https://t.co/vnBnFcPxGw
Dr. John Cush @RheumNow ( View Tweet)
🆕 ILD (Part II): advanced insights
🫁 Multidisciplinary management
💊 Treatment strategies
📊 Prognosis & monitoring
🧑⚕️ What rheums should know next
⬇️ Download & learn more: https://t.co/dmhULfqiMj
Created by
@MithuRheum | For our Rheum to Breathe: ILD Campaign https://t.co/ivvDjxkCvt
Dr. John Cush @RheumNow ( View Tweet)
SUA levels & adverse health outcomes? Australian ASPREE trial of 11,878 older participants had baseline SUA measurements. SUA levels had NO ASSOC. w/ all-cause mortality, disability-free survival, CV Dz, MACE, cancer mortality, cognitive decline, or dementia. In females, low SUA https://t.co/VY6NJsetW9
Dr. John Cush @RheumNow ( View Tweet)
Non-Pharmacologic ILD Care
Jon T. Giles, MD, MPH, discusses non-Pharmacologic approaches to ILD treatment and patient care. Sponsored By: Boehringer Ingelheim
https://t.co/Mxg9P50m7C
#ILD #Rheumatology https://t.co/5wD1K7J1Gq
Dr. John Cush @RheumNow ( View Tweet)
Study of 43 PsA pts starting bDMARD shows Calprotectin was elevated in PsA, decreased w/ biologics, but had no signif correlation w/ US synovitis. Baseline calprotectin, S100A12, IL-6, IL-17A, IL-23, CXCL10 were high. Calprotectin, S100A12, IL-6 decreased w/ Rx (p < 0.05).
Dr. John Cush @RheumNow ( View Tweet)
QD Clinic: Beyond the Numbers in Newly Diagnosed ILD
Dr. Eric Dein, Summit, NJ, presents a case of a new patient with interstitial lung disease, as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025.
https://t.co/HLnX5WbbTw https://t.co/SZeI4bqSAm
Dr. John Cush @RheumNow ( View Tweet)
From the blog
Podcasts
Controversies in ILD
APLAR Congress 2025
QD clinics on ILD - lessons from the Clinic
Ro, Ro, Ro52 (9.12.2025)
Therapeutic Updates
Watch our 9 video series on ILD Treatment and Guidelines including videos on the ACR ILD Guidelines including caveats and concerns.
Read Post
Structural damage progression in active PsA
Sponsored by Johnson & Johnson
Watch Dr. Philip Mease discuss the impact of structural damage on active PsA and follow along as he reviews clinical trial data
Read Post
Poster Hall
Sponsored by AbbVie Medical Affairs + Health Impact
